Regulation of PD-L1 expression in the tumor microenvironment

被引：450

作者：

Yi, Ming ^{[1
]}

Niu, Mengke ^{[1
,2
,3
]}

Xu, Linping ^{[2
,3
]}

Luo, Suxia ^{[2
,3
]}

Wu, Kongming ^{[1
,2
,3
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan 430030, Peoples R China

[2] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China

[3] Henan Canc Hosp, Zhengzhou 450008, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2021年 / 14卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Cancer immunology; PD-L1; PD-1; Transcriptional regulation; Post-transcriptional modification; PROMOTES ANTITUMOR IMMUNITY; SQUAMOUS-CELL CARCINOMA; PD-LL EXPRESSION; NF-KAPPA-B; LUNG-CANCER; UP-REGULATION; TNF-ALPHA; TGF-BETA; SIGNALING PATHWAYS; DENDRITIC CELLS;

D O I：

10.1186/s13045-020-01027-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from alpha-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.

引用

页数：13

共 153 条

[1] MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function [J].

Ahn, Hyun Kyung ;

Kim, Sehui ;

Kwon, Dohee ;

Koh, Jaemoon ;

Kim, Young A. ;

Kim, Kwangsoo ;

Chung, Doo Hyun ;

Jeon, Yoon Kyung .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics [J].

Akinleye, Akintunde ;

Rasool, Zoaib .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)

[4] Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy [J].

Al Emran, Abdullah ;

Chatterjee, Aniruddha ;

Rodger, Euan J. ;

Tiffen, Jessamy C. ;

Gallagher, Stuart J. ;

Eccles, Michael R. ;

Hersey, Peter .

TRENDS IN IMMUNOLOGY, 2019, 40 (04) :328-344

[5]

Albitar Maher, 2018, Oncotarget, V9, P13682, DOI 10.18632/oncotarget.24455

[6] Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas [J].

Anastasiadou, Eleni ;

Stroopinsky, Dina ;

Alimperti, Stella ;

Jiao, Alan L. ;

Pyzer, Athalia R. ;

Cippitelli, Claudia ;

Pepe, Giuseppina ;

Severa, Martina ;

Rosenblatt, Jacalyn ;

Etna, Marilena P. ;

Rieger, Simone ;

Kempkes, Bettina ;

Coccia, Eliana M. ;

Sui, Shannan J. Ho ;

Chen, Christopher S. ;

Uccini, Stefania ;

Avigan, David ;

Faggioni, Alberto ;

Trivedi, Pankaj ;

Slack, Frank J. .

LEUKEMIA, 2019, 33 (01) :132-147

[7] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[8] PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma [J].

Asgarova, A. ;

Asgarov, K. ;

Godet, Y. ;

Peixoto, P. ;

Nadaradjane, A. ;

Boyer-Guittaut, M. ;

Galaine, J. ;

Guenat, D. ;

Mougey, V. ;

Perrard, J. ;

Pallandre, J. R. ;

Bouard, A. ;

Balland, J. ;

Tirole, C. ;

Adotevi, O. ;

Hendrick, E. ;

Herfs, M. ;

Cartron, P. F. ;

Borg, C. ;

Hervouet, E. .

ONCOIMMUNOLOGY, 2018, 7 (05)

[9] miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1 [J].

Ashizawa, Mai ;

Okayama, Hirokazu ;

Ishigame, Teruhide ;

Min, Aung Kyi Thar ;

Saito, Katsuharu ;

Ujiie, Daisuke ;

Murakami, Yuko ;

Kikuchi, Tomohiro ;

Nakayama, Yuko ;

Noda, Masaru ;

Tada, Takeshi ;

Endo, Hisahito ;

Fujita, Shotaro ;

Sakamoto, Wataru ;

Saito, Motonobu ;

Saze, Zenichiro ;

Momma, Tomoyuki ;

Ohki, Shinji ;

Mimura, Kosaku ;

Kono, Koji .

MOLECULAR CANCER RESEARCH, 2019, 17 (06) :1403-1413

[10] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma [J].

Atefi, Mohammad ;

Avramis, Earl ;

Lassen, Amanda ;

Wong, Deborah J. L. ;

Robert, Lidia ;

Foulad, David ;

Cerniglia, Michael ;

Titz, Bjoern ;

Chodon, Thinle ;

Graeber, Thomas G. ;

Comin-Anduix, Begonya ;

Ribas, Antoni .

CLINICAL CANCER RESEARCH, 2014, 20 (13) :3446-3457

← 1 2 3 4 5 6 7 8 9 10 →